Late-stage data backs new application for Aloxi

MGI Pharma and Helsinn Healthcare plan to file a new marketing application for the nausea drug Aloxi after two late-stage trials demonstrated its effectiveness against nausea and vomiting after surgery. The data demonstrated a complete response by patients up to 72 hours after surgery. The drug is already approved to prevent nausea and vomiting after chemotherapy.

- here's the AP report on the new data

Related Articles:
Exelixis shares sink after Helsinn halts study. Report
FDA approves MGI's Dacogen for MDS. Report